These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. Hamsten A; Wiman B; de Faire U; Blombäck M N Engl J Med; 1985 Dec; 313(25):1557-63. PubMed ID: 3934538 [TBL] [Abstract][Full Text] [Related]
30. Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Juhan-Vague I; Alessi MC; Raccah D; Aillaud MF; Billerey M; Ansaldi J; Philip-Joet C; Vague P Thromb Haemost; 1992 Jan; 67(1):76-82. PubMed ID: 1615488 [TBL] [Abstract][Full Text] [Related]
31. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies. Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090 [TBL] [Abstract][Full Text] [Related]
32. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Paola Cellai A; Antonucci E; Alessandrello Liotta A; Fedi S; Marcucci R; Falciani M; Giglioli C; Abbate R; Prisco D Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869 [TBL] [Abstract][Full Text] [Related]
33. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC]. Nagaizumi K; Kuroso K; Amano K; Sato T; Fukutake K; Fujimaki M Rinsho Byori; 1994 Jul; 42(7):707-12. PubMed ID: 8065036 [TBL] [Abstract][Full Text] [Related]
34. Levels of activated FXII in survivors of myocardial infarction--association with circulating risk factors and extent of coronary artery disease. Kohler HP; Carter AM; Stickland MH; Grant PJ Thromb Haemost; 1998 Jan; 79(1):14-8. PubMed ID: 9459314 [TBL] [Abstract][Full Text] [Related]
35. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction. Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173 [TBL] [Abstract][Full Text] [Related]
36. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator. Huber K; Beckmann R; Rauscha F; Probst P; Kaindl F; Binder BR Z Kardiol; 1993; 82 Suppl 2():195-200. PubMed ID: 8328203 [TBL] [Abstract][Full Text] [Related]
37. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Gardemann A; Lohre J; Katz N; Tillmanns H; Hehrlein FW; Haberbosch W Thromb Haemost; 1999 Sep; 82(3):1121-6. PubMed ID: 10494775 [TBL] [Abstract][Full Text] [Related]
38. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease. Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383 [TBL] [Abstract][Full Text] [Related]
39. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Tran-Thang C; Fasel-Felley J; Pralong G; Hofstetter JR; Bachmann F; Kruithof EK Thromb Haemost; 1989 Sep; 62(2):651-3. PubMed ID: 2510345 [TBL] [Abstract][Full Text] [Related]